TFX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TFX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Teleflex's EBITDA for the three months ended in Dec. 2024 was $-36 Mil. Teleflex's Revenue for the three months ended in Dec. 2024 was $795 Mil. Therefore, Teleflex's EBITDA margin for the quarter that ended in Dec. 2024 was -4.57%.
The historical data trend for Teleflex's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teleflex Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
EBITDA Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
25.68 | 30.39 | 26.18 | 25.59 | 14.23 |
Teleflex Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EBITDA Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
19.38 | 8.53 | 24.92 | 28.81 | -4.57 |
For the Medical Instruments & Supplies subindustry, Teleflex's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Teleflex's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Teleflex's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Teleflex's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as
Teleflex's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teleflex (NYSE:TFX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of Teleflex's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Stuart A Randle | director | 585 WEST 500 SOUTH, BOUNTIFUL UT 84010 |
Cameron P Hicks | officer: Vice President, Global HR | 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087 |
Liam Kelly | officer: EVP & President, International | IDA BUSINESS AND TECHNOLOGY PARK, DUBLIN ROAD, ATHLONE L2 00000 |
Thomas E Powell | officer: Senior Vice President & CFO | C/O TOMOTHERAPY INCORPORATED, 1240 DEMING WAY, MADISON WI 53717 |
Jaewon Ryu | director | 950 N. GLEBE ROAD, SUITE 700, ARLINGTON VA 22203 |
Neena M Patil | director | JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Andrew A Krakauer | director | CANTEL MEDICAL CORP., 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424 |
Klasko Stephen K. M.d. | director | 155 SOUTH LIMERICK ROAD, LIMERICK PA 19468 |
Jay White | officer: VP & Pres, Global Commercial | 3015 CARRINGTON MILL BLVD., MORRISVILLE NC 27560 |
Daniel V. Logue | officer: VP, Gen Counsel & Secretary | 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087 |
John Deren | officer: VP & Chief Accounting Officer | 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087 |
James J Leyden | officer: VP, General Counsel, Secretary | C/O INFRASOURCE SERVICES, INC, 500 WEST DUTTON MILL ROAD, ASTON PA 19014 |
James Winters | officer: Vice President, Mfg and Supply | 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087 |
Mario Wijker | officer: Vice President, QARA | 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087 |
Benson Smith | director | C/O ROCHESTER MEDICAL INC, ONE ROCHESTER MEDICAL DDRIVE, STEWARTVILLE MN 55976 |
From GuruFocus
By Marketwired • 03-06-2025
By Marketwired • 02-27-2025
By GuruFocus News • 02-27-2025
By GuruFocus News • 02-27-2025
By Business Wire • 02-27-2025
By GuruFocus News • 02-14-2025
By Marketwired • 02-27-2025
By Marketwired • 03-02-2025
By Marketwired • 02-27-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.